ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Hengrui Gets Okay For U.S. Trials

by Jean-François Tremblay
August 31, 2009 | APPEARED IN VOLUME 87, ISSUE 35

Shanghai-based Hengrui Pharmaceuticals has obtained FDA’s approval to start Phase I human trials in the U.S. for retagliptin, a compound for treating type 2 diabetes. The company says it is the first China-based company to get a green light for U.S. testing of a small-molecule drug invented in China. Belonging to the same class of compounds as Merck & Co.’s sitagliptin drug, retagliptin is another type of dipeptidyl peptidase-4 inhibitor.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment